tiprankstipranks
Leerink remains bullish on Eli Lilly despite lower Q4 revenue guidance
The Fly

Leerink remains bullish on Eli Lilly despite lower Q4 revenue guidance

Leerink notes that Eli Lilly (LLY) lowered its Q4 total revenue guidance by 5% but issued initial 2025 revenue guidance 2% above consensus. Q4 Mounjaro and Zepbound sales were approximately 18% and 15% below consensus, respectively. Although this is the second quarter in a row of disappointing results, the firm expects 2025-plus financial performance and pipeline news flow to be encouraging. Leerink reiterates its Outperform rating on the shares.

Stay Ahead of the Market:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles